ASKA Pharmaceutical Holdings Co.,Ltd. [4886.T]
TOKYO, May 11 (Pulse News Wire) – Aska Pharmaceutical Holdings CO.,LTD. (4886.T) reported robust fourth-quarter results for the fiscal year ending March 2026, with operating profit reaching ¥62 billion, up from the prior year.
Revenue surged to ¥71.10 billion, marking a significant increase compared to the same period last year. The strong performance was driven by solid growth in domestic pharmaceutical sales and contributions from overseas operations. Key products such as Relmina, Droethi, and Chlazim showed substantial gains, bolstering overall revenue.
Despite challenges posed by price adjustments, the company's focus on strategic product lines helped maintain profitability. For the fiscal year ending March 2027, ASKA forecasts continued growth, projecting revenues of ¥73.00 billion and operating profits of ¥65.6 billion, representing increases of 3.8% and 5.8%, respectively. The outlook reflects anticipated benefits from new product launches and ongoing cost management initiatives.
In addition, ASKA highlighted its progress in research and development, with several key projects advancing through Phase III trials, positioning the company well for future growth opportunities.
🔴 Confidence: Review recommended AI-translated content.